Zonal Retardation Chromatography for Weak Affinity Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current high-throughput screening methods are limited in detecting weak affinity drug candidates due to their inability to measure transient interactions, which are essential for drug discovery, as traditional techniques can only detect strong interactions and are not designed for high-throughput analysis of weak binders.
Innovation Solution
A method utilizing zonal retardation chromatography to identify candidate drug molecules with weak affinity by screening a biological target for transient interactions with a library of ligands, collecting zonal retardation information to select ligands with dissociation constants in the range of 0.01 to 10 mM, and further analyzing their binding behavior using NMR.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional high-throughput screening methods are used, then screening speed and productivity are improved, but the ability to detect weak affinity interactions is lost
Solution Approach 1:
The patent employs dynamic zonal retardation chromatography where ligands are continuously transported past the stationary phase containing the biological target. This dynamic flow system allows transient weak interactions to be captured and measured through retention time analysis, enabling high-throughput screening of weak binders while maintaining detection sensitivity
Solution Approach 2:
The patent replaces traditional mechanical binding assays with a chromatographic system based on zonal retardation. Instead of measuring direct binding events, the system measures the retardation effect of weak interactions on ligand migration through the stationary phase, allowing weak affinity detection with high throughput capability
2Reliability
If traditional binding assays are used, then strong interactions can be detected, but transient weak interactions are washed away and cannot be measured
Solution Approach 1:
The patent changes the detection parameter from direct binding measurement to retention time measurement in a flowing system. By monitoring how long ligands are retained on the stationary phase, the system can detect weak interactions that would otherwise be washed away, expanding the detection range to include transient binders with Kd values from nM to mM range
3Manufacturing precision
If affinity chromatography is used for purification, then protein purity is improved, but high-throughput screening capability is reduced
Solution Approach 1:
The patent segments the chromatography system into multiple parallel channels or wells, allowing simultaneous screening of multiple ligands. This segmentation maintains the purification quality of affinity chromatography while achieving high-throughput capability by processing multiple samples in parallel rather than sequentially
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables rapid screening and selection of potential drug molecules with weak affinity, providing instant information on affinity and kinetics, and demonstrating potential for parallel and multi-well plate formats, capable of handling thousands of samples per day.
Implementation Method 1
transporting a plurality of ligand compositions to said stationary phases, thereby establishing contacts between said ligands and said biological targets; collecting, downstream of said stationary phases, zonal retardation information for each ligand
Data Source
AI summary
The present invention relates to a method of screening a biological target for transient weak interactions between the target and a library of ligands. The method includes the provision of a composition comprising a biological target and the provision of a plurality of stationary phases from such a composition. A plurality of ligand compositions is transported to the stationary phases to establish contacts between the ligands and the biological targets. Zonal retardation information are collected for each ligand, downstream of the stationary phases in order to select ligands with dissociation constants (Kd) in the range of 0.01 to 10 mM, exhibiting weak affinity to the target.